Drugs / APR002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05268198 | Mar → Jun 2023 | COVID-19 | Global Health Drug Discovery Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APR002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05268198 ↗ |
| Action | Activate | “TLR7 agonist” NCT05268198 ↗ |
| Route | Inhaled | “APR002 Administered by Inhalation” NCT05268198 ↗ |
| Target | TLR7 | “TLR7 agonist” NCT05268198 ↗ |